-
Welcome to Celiac.com!
You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.
-
Celiac.com Sponsor (A1):
Celiac.com Sponsor (A1-M):
-
Get Celiac.com Updates:Support Our Content
Search the Community
Showing results for tags 'stanford'.
-
Celiac.com 04/26/2022 - Celiac disease research, diagnosis, support and treatment just got a big shot in the arm with the launch of Stanford's new Center for Pediatric Inflammatory Bowel Disease (IBD) and Celiac Disease. Made possible by a $70 million gift from an anonymous donor, the center aims to make a major contribution to improving the lives of young patients who suffer from inflammatory bowel and celiac disease. Because many kids with IBD and celiac disease need comprehensive and dedicated care to get the best results, the new center will unite expert clinicians, researchers, IBD and celiac disease nurses, dietitians, psychologists, and social workers, to offer world-class clinical care for kids with IBD and celiac disease. In addition, the center will provide treatment for Crohn’s disease, ulcerative colitis, indeterminate colitis and very-early-onset IBD. To meet the wide-ranging care needs of children across the spectrum of IBD and celiac disease severity, the center will work closely with top pediatric specialists in a number of areas, including advanced endoscopy, surgery, pain management, mental health, nutrition and integrative medicine at Stanford. Researchers and clinicians will work with Stanford Medicine scientists in microbiome science, human immunology, genetics, epithelial biology, biomedical engineering and data science to explore the origins of IBD and celiac disease in children, improve drugs, and help develop new treatments. One advantage of this approach is that the "collaboration with expert clinical immunologists and geneticists enables us to provide advanced diagnostic and treatment options to children with IBD and celiac disease disorders that do not respond to standard treatment,” said Center director, Dr. Michael J. Rosen. Dr. Rosen describes the center as the “...nation’s destination center for innovation in pediatric IBD and celiac disease care, as well as a major research hub for these conditions,” adding that the center's joint services "will give children from birth to age 22 the best chance to live full and productive lives,” Dr. Rosen said. In addition to being a pediatric gastroenterologist at Stanford Children’s Health, Dr. Rosen is also the Stanford University Endowed Professor for Pediatric IBD & Celiac Disease. Experts in the center will also work to speed up knowledge of these chronic diseases, collect and share data, and synchronize approaches to improve diagnosis and treatment. This collaborative approach can help the center to "personalize treatment, curate biospecimens and patient-reported outcomes data for the world’s investigators and develop clear guidance on which drugs are safest and most effective for each child,” adds Dr. Rosen. For more information, check the website for the Center for Pediatric IBD and Celiac Disease Read more at Stanford.edu
-
- celiac disease
- children
- (and 7 more)
-
Celiac.com 05/12/2006 - Dear Colleagues in the Celiac Community: We would like to provide you with a progress report of the Celiac Management Clinic (CMC) at Stanford Medical Center. Realizing that many physicians and gastroenterologists have a limited understanding of the frequency of Celiac Sprue in the population and the subtlety of the clinical manifestations of this disease, we instituted the CMC at Stanford Medical Center in January 2005. This clinic is staffed by Dr. Gail Pyle and myself. A large number of patients who carried the diagnosis of Celiac Sprue have chosen to be seen in consultation--the majority of these did have Celiac Sprue, as estimated from blood antibody tests and the small intestinal (duodenal) biopsy. For many of these patients, comprehensive emphasis on gluten exclusion has been very effective in eliminating symptoms and the malabsorption of nutrients. However, both in this patient group and in those healthy gluten-free Celiac volunteers who participated in the trial supported by the Celiac Sprue Research Foundation in collaboration with the Palo Alto Medical Foundation on pre-treatment of grocery store gluten with a special peptidase(1) there was a surprising discovery. Fully half (~50%) of those presumed to be in remission from the disease had malabsorption of important nutrients. This major finding was a surprise, and it gives us pause concerning Celiac Sprue therapy. Is gluten exclusion not optimal or is it insufficient therapy for this large proportion of Celiac Sprue patients? The concerns about the effectiveness of long-term dietary therapy in Celiac Sprue have prompted us to reassess our approach to this disease. For those of you who reside within reach of Stanford Medical Center, we invite you to visit us at the Celiac Management Clinic for an up-to-date assessment of the status of your Celiac condition. If you are the one out of every two healthy Celiacs with malabsorption, we will take a comprehensive approach to determine the reasons and to facilitate your return to complete remission. If strict gluten exclusion is insufficient to achieve this, we offer other approaches. Indeed, by the end of this year or the beginning of 2007 in collaboration with the Celiac Sprue Research Foundation, we expect to be able to determine the effect of an oral pill therapy for those who continue with malabsorption of nutrients. Stanford accepts most PPO insurance and MediCal and MediCare outpatient coverages. Those who suspect they have Celiac Sprue based on symptoms or blood antibody tests will be seen by Dr. Gray, and those with biopsy-verified disease will be seen by Dr. Pyle. For an appointment, call 650-723-6961, and please state that you wish to see us at the Celiac Management Clinic. Sincerely, Gary M Gray, M.D. Professor of Medicine, Emeritus (Gastroenterology) References: Pyle GG, Paaso, B Anderson, BE, Allen D, Marti T, Chaitan Khosla C, Gray, GM. Low-dose Gluten Challenge in Celiac Sprue: Malabsorptive and Antibody Responses. Clinical Gastroenterology and Hepatology, 3: 679-686, 2005. Pyle GG, Paaso, B Anderson, BE, Allen D, Marti T, Li Q, Matthew Siegel, M, Khosla C, Gray, GM. Effect of Pretreatment of Food Gluten With Prolyl Endopeptidase on Gluten-Induced Malabsorption in Celiac Sprue Clinical Gastroenterology and Hepatology, 3: 687-694, 2005.
-
Celiac.com 04/24/2020 - We've all heard of smart phones and smart TVs, but what about smart toilets? You heard right. In the near future, a simple trip to the bathroom might provide a medical diagnosis for celiac or numerous other diseases and medical conditions. Researchers at Stanford University have created a toilet attachment that can analyze urine and feces for common diseases and medical conditions, such as celiac disease, and irritable bowel syndrome, among others. The sensor attaches to the inside of the toilet bowl, records samples, and analyzes the results using complex software. Results are then stored in the cloud for doctors to review. Aside from taking readings to diagnose disease, the toilet works exactly the same as any other toilet, which is part of the plan. “The user doesn’t have to do anything differently,” said lead author Sanjiv Gambhir. Since everyone uses the bathroom, the smart toilet offers clinicians a reliable way to collect patient data, which unlike wearable technology, cannot be forgotten. The smart toilet won't be taking the place of a doctor, nor will it be providing diagnosis directly to the patient. "In fact, in many cases," says Gambhir, "the toilet won’t ever report data to the individual user.” Turns out you bum hole is every bit as unique as your fingerprint, which means it can be used to identify any given user. In the same way a smartphone can identify users with fingerprints or facial scans, the smart toilet can do the same with an anal print. The reason for this is that more and more toilets are hands-free, so making sure the data is properly recorded for each user becomes an issue. With anal recognition technology, the smart toilet can identify each user with complete accuracy. You won't find the smart toilet online just yet. The device is currently only for use on test subjects at Stanford. The development team is still working to accurately improve the toilet, and they are working to develop modules that detect symptoms and illnesses like dehydration, enlarged prostate, including "cancers and COVID-19," says senior researcher Seung-min Park Read more at Medgadget.com
- 3 comments
-
- celiac
- celiac disease
- (and 7 more)
-
Celiac.com 09/30/2002 - As reported in the September 27, 2002 issue of Science, Dr. Chaitan Khosla, professor of chemistry and chemical engineering at Stanford University, and colleagues have identified the specific protein fragment that causes intestinal damage when people with celiac disease eat grains such as wheat, rye, and barley. Graduate student Lu Shan from the Stanford team was able to identify the specific protein fragment in gluten that triggers the damaging attack by T-cells in individuals with the disease. The key fragment is made up of 33 amino acids that are normally broken down in the digestive systems of healthy individuals, but not in those with celiac disease. In addition to this discovery, the Stanford team is also beginning their search for a celiac disease cure. To that end they have developed an enzyme treatment that renders the newly discovered harmful amino acid sequence in gluten harmless in the guts of test animals, and hope that it will do the same in humans. Several more years of research must be done in order to determine if it will be effective in humans. Dr. Khosla warns against undue optimism regarding the preliminary results of their new enzyme therapy, and stresses that it is too early to raise the hopes of those with celiac disease. To fund the teams future research efforts Dr. Khosla and colleagues have established the Celiac Sprue Research Foundation, whose goal is finding a cure for the disease. The foundation must raise two million dollars by 2003 in order to begin serious scientific research to that end. Anyone interested in making a tax deductible contribution should go to their Web site: www.celiacsprue.org. I personally believe that the work of the Celiac Sprue Research Foundation represents our best shot at a cure for celiac disease. - Scott Adams, Celiac.com. Medline Abstract: Intestinal Digestive Resistance of Immunodominant Gliadin Peptides. Am J Physiol Gastrointest Liver Physiol 2002 Oct;283(4):G996-G1003 Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Department of Chemical Engineering, Stanford University, Stanford, California 94305-5025. Two recently identified immunodominant epitopes from alpha-gliadin account for most of the stimulatory activity of dietary gluten on intestinal and peripheral T lymphocytes in patients with celiac sprue. The proteolytic kinetics of peptides containing these epitopes were analyzed in vitro using soluble proteases from bovine and porcine pancreas and brush-border membrane vesicles from adult rat intestine. We showed that these proline-glutamine-rich epitopes are exceptionally resistant to enzymatic processing. Moreover, as estimated from the residual peptide structure and confirmed by exogeneous peptidase supplementation, dipeptidyl peptidase IV and dipeptidyl carboxypeptidase I were identified as the rate-limiting enzymes in the digestive breakdown of these peptides. A similar conclusion also emerged from analogous studies with brush-border membrane from a human intestinal biopsy. Supplementation of rat brush-border membrane with trace quantities of a bacterial prolyl endopeptidase led to the rapid destruction of the immunodominant epitopes in these peptides. These results suggest a possible enzyme therapy strategy for celiac sprue, for which the only current therapeutic option is strict exclusion of gluten-containing food. PMID: 12223360
Celiac.com Sponsor (A8):
Celiac.com Sponsor (A8):
Celiac.com Sponsor (A8-M):
Celiac.com Sponsor (A8):
Celiac.com Sponsor (A8):
Celiac.com Sponsor (A8-M):